(NASDAQ: FBRX) Forte Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.06%.
Forte Biosciences's earnings in 2026 is -$75,855,000.On average, 7 Wall Street analysts forecast FBRX's earnings for 2026 to be -$91,032,437, with the lowest FBRX earnings forecast at -$95,930,970, and the highest FBRX earnings forecast at -$83,215,673. On average, 7 Wall Street analysts forecast FBRX's earnings for 2027 to be -$89,945,012, with the lowest FBRX earnings forecast at -$118,207,827, and the highest FBRX earnings forecast at -$70,098,991.
In 2028, FBRX is forecast to generate -$92,535,582 in earnings, with the lowest earnings forecast at -$112,989,825 and the highest earnings forecast at -$62,788,053.